BPC-157 Certificate of Analysis: What Laboratory Results Mean

A BPC-157 certificate of analysis can look reassuring at first glance. It may display a purity percentage, a chromatogram, a laboratory name, and a batch number. But these details do not all prove the same thing, and none should be interpreted without understanding how the material was tested.

For scientific readers, the key is to separate a reported analytical result from the conclusion someone wants to draw from it. A certificate may support claims about a tested sample’s identity or composition, depending on the methods used. It does not automatically establish clinical safety, effectiveness, or suitability for a particular application.

1. Start With the Document, Not the Purity Percentage

Before reviewing any laboratory result, establish what the document actually covers.

A certificate of analysis should identify the material being tested and connect the reported findings to a specific sample or batch. The exact fields vary by laboratory and testing programme, but a useful document typically includes several core details.

Document field	What to check	Why it matters
Compound name	Does it clearly identify the material?	Similar or inconsistent names can create confusion.
Batch or lot number	Is a unique identifier provided?	It helps connect the report to a particular batch.
Sample identification	Is the tested sample clearly described?	It establishes what the results refer to.
Test date	When was the analysis performed?	It helps establish the timing of the reported findings.
Analytical methods	Which methods were used?	Different methods answer different questions.
Results and units	Are the values and measurement units stated?	Results need context to be interpreted correctly.
Laboratory details	Is the testing organisation identifiable?	It allows readers to assess the source and traceability of the report.
Authorisation or approval	Is the report signed or otherwise authenticated?	It may help establish document accountability, depending on the laboratory’s process.

A missing field does not automatically prove that a report is fraudulent. However, missing information can make it harder to verify the document or determine how much confidence to place in its findings.

The first question should always be: What sample was tested, and what does this report actually establish about it?

2. Understand What the Purity Percentage Means

Purity is one of the most prominent figures on peptide laboratory reports. It is also one of the easiest results to misunderstand.

High-performance liquid chromatography (HPLC) separates components in a sample so that they can be detected and analysed. In some peptide reports, the laboratory calculates a percentage from the relative detector responses of peaks in a chromatogram. This is often described as area-percent purity or chromatographic purity.

The distinction is important because a chromatographic area percentage is not necessarily the same as the percentage of the sample’s total mass represented by the target peptide.

Different compounds may respond differently to a detector. Some impurities may be difficult to detect under the selected conditions, and a method may not distinguish every relevant substance. Results also depend on the sample preparation, separation conditions, detection system, and calculation method.

For that reason, a reported purity value should be interpreted alongside the method used to obtain it.

Questions to ask about a purity result

• Does the report identify the method used to calculate purity?
• Does it explain whether the result is based on chromatographic peak areas or another measurement?
• Are the testing conditions and detection method described?
• Does the report provide enough information to interpret the result in context?
• Are limitations or excluded impurities documented?

A high reported percentage may be useful analytical information, but it should not be presented as a complete measure of product quality without supporting evidence.

For more background, see our guide to [BPC-157 purity testing], which explains how chromatograms and analytical methods should be interpreted.

3. Identity Testing and Purity Testing Are Different

One of the most important distinctions in laboratory analysis is the difference between identifying a compound and estimating its purity.

Identity testing asks whether the material is consistent with the substance it is claimed to be. Depending on the compound and analytical approach, this may involve mass spectrometry, sequence-related analysis, or other suitable techniques.

Purity testing assesses the presence or relative amount of components under the conditions of the chosen method. It may help identify additional chromatographic peaks, but a peak alone does not necessarily reveal the chemical identity of the substance producing it.

A report that contains an HPLC purity result but no suitable identity test may therefore leave an important question unanswered.

Mass spectrometry can provide information about molecular mass and, with appropriate methods, additional structural details. However, a mass result by itself does not always distinguish compounds with similar masses or establish the complete amino-acid sequence. The method must be appropriate for the question being asked.

The strongest interpretation comes from complementary methods whose capabilities and limitations are understood. It should not assume that one analytical result answers every question about the sample.

4. Read the Chromatogram Carefully

An HPLC chromatogram is a plot showing detector response over time as components pass through the analytical system. Each visible peak represents a detector response under the selected conditions.

A report may label the main peak as the target peptide and provide a retention time and area percentage. These values can help describe the analytical result, but they require context.

Retention time

Retention time is the time taken for a component to reach the detector after injection. It can help compare a sample with a suitable reference under the same method conditions.

A matching retention time alone does not prove identity. Different substances may elute at similar times, and changes in the method can affect retention behaviour.

Additional peaks

Additional peaks may indicate impurities, degradation products, related substances, or other components. Their interpretation depends on the method and available reference information.

The absence of visible additional peaks does not prove that the sample contains no impurities. Some substances may not be detected effectively under the conditions used.

Peak-area calculations

Peak-area percentages describe the distribution of detected signal under the calculation approach used. They should not automatically be interpreted as exact mass percentages.

A reliable report should provide enough method information to explain what the calculation represents and what its limitations are.

5. Check the Batch and Sample Traceability

A technically detailed report is less useful if the reader cannot establish which material it represents.

Batch traceability links a report to a particular sample or production lot. Check whether the lot number on the certificate matches the lot identification on the associated documentation. Look for sample identifiers, report numbers, test dates, and any stated chain-of-custody information.

If a report is being used to support a claim about a particular batch, it is important to know whether the laboratory tested that batch or a different sample.

A report for one batch should not automatically be treated as evidence for every later batch. Likewise, a general specification sheet is not necessarily equivalent to a certificate documenting actual results for a defined sample.

If information is missing or inconsistent, the appropriate response is to seek clarification from the issuing laboratory or responsible organisation rather than assume that the document proves or disproves a claim.

6. Assess the Laboratory and the Method

The laboratory name is only one part of the evidence. It is also important to understand the methods used and whether they were suitable for the stated purpose.

Analytical method validation evaluates whether a method performs adequately for its intended application. Depending on the method and purpose, relevant characteristics can include specificity, accuracy, precision, detection capability, quantitation capability, and robustness.

The importance of each characteristic depends on the measurement being made. A method intended to compare chromatographic profiles may not answer the same questions as a method designed to quantify a substance in a defined matrix.

The International Council for Harmonisation (ICH) provides guidance on analytical procedure validation, including Q2(R2), which discusses validation principles for analytical procedures used in pharmaceutical quality assessment.

Reference: ICH Quality Guidelines.

The US Food and Drug Administration also publishes guidance on analytical procedures and methods validation for drugs and biologics.

Reference: FDA: Analytical Procedures and Methods Validation for Drugs and Biologics.

These resources help explain why a result should be judged in relation to its method, purpose, and supporting documentation, rather than by a headline percentage alone.

7. What a Certificate of Analysis Cannot Prove

Even a detailed CoA has a defined scope. It should not be treated as a universal guarantee of product quality.

A certificate does not automatically establish:

• Clinical safety: Analytical results alone cannot establish how a substance affects people.
• Clinical effectiveness: Purity or identity results do not demonstrate a beneficial clinical outcome.
• Regulatory approval: A laboratory report does not establish that a substance is authorised as a medicine.
• Complete absence of contaminants: This depends on the contaminants considered, the methods used, and their detection capabilities.
• Equivalence between products: Two materials with similar names or reported purity values may differ in identity, formulation, impurities, or other characteristics.
• Validity for every batch: Results apply to the sample tested, within the limits of the analysis and the document’s scope.

The FDA has raised specific safety concerns regarding certain bulk drug substances involving BPC-157 and thymosin beta-4-related fragments. Those concerns reinforce the need to distinguish analytical documentation from evidence of human safety.

Reference: FDA information on bulk drug substances that may present significant safety risks.

8. A Practical CoA Review Checklist

When evaluating a BPC-157 certificate for research documentation, use this checklist to organise the review.

• Confirm the compound name and available molecular identity information.
• Match the report to a clearly identified sample or batch.
• Identify the analytical methods used.
• Determine whether identity testing and purity testing are both addressed.
• Check how the purity result was calculated.
• Review the chromatogram and any reported additional peaks.
• Look for relevant method limitations and validation information.
• Verify laboratory details and document authenticity where possible.
• Confirm that the conclusions being drawn do not exceed the scope of the report.

This checklist is a way to assess documentation, not a certification that a sample is safe or suitable for any particular use.

Frequently Asked Questions

What should a BPC-157 certificate of analysis include?

A useful certificate generally identifies the material and tested sample, provides batch or sample identifiers, describes the analytical methods, reports results with appropriate units, and identifies the testing laboratory. The exact requirements depend on the purpose of the analysis.

Does 99% HPLC purity mean a sample is 99% BPC-157 by weight?

Not necessarily. A reported chromatographic area percentage may describe the relative detector response of detected peaks. It should not automatically be treated as a mass percentage without suitable supporting methodology.

Can HPLC confirm BPC-157 identity?

HPLC can provide useful chromatographic information, but retention time or a main peak alone may not conclusively establish molecular identity. Additional suitable analytical methods may be required.

Does mass spectrometry prove a peptide is safe?

No. Mass spectrometry can provide information about molecular mass and, depending on the technique, structural characteristics. It does not independently establish clinical safety or effectiveness.

Can a CoA from one batch be used for another?

Not automatically. A report should be linked to the sample or batch actually tested. Results from one batch do not establish that another batch has identical characteristics.

Conclusion

A BPC-157 certificate of analysis is most useful when its results are interpreted within the limits of the analytical methods used. Purity percentages, chromatograms, identity tests, and batch identifiers provide different types of information, and they should not be treated as interchangeable evidence.

The central principle is straightforward: verify what was tested, understand how the result was produced, and avoid conclusions that the report cannot support. A CoA can contribute to analytical documentation, but it is not proof of clinical safety, effectiveness, or regulatory approval.

Research disclaimer: This article is for scientific and educational purposes only. It does not recommend the purchase, administration, or use of experimental peptides and is not medical advice. Analytical documentation should be interpreted by appropriately qualified personnel in the context of the method and intended research purpose.